Because each acquired DSA typically recognizes 1 HLA specificity, opportunities to obtain EC expressing the relevant HLA allele are very limited. However, a significant subset of transplantation candidates are highly sensitized before transplantation, having high-titer polyclonal mixtures of panelreactive antibodies (PRAs) in their serum that recognize many different nonself HLA specificities. 18 PRA, like DSA, can activate complement and cause antibody-mediated rejection, 19 serving as a useful tool to model the effects of DSAs on ECs. 20 Here, we report that, PRA activates cultured human ECs that had been pretreated with IFN-γ, enhancing the capacity of ECs to recruit and activate allogeneic T cells. Complement membrane attack complex (MAC), formed in response to binding of PRA, activates noncanonical (but not canonical) nuclear factor-κB (NF-κB) signaling in ECs, a pathway necessary for enhancing EC-mediated T-cell responses. Noncanonical NF-κB signaling is activated both in the ECs of allograft biopsies from renal transplantation patients with CAMR, but not control biopsies, and in ECs lining human coronary arteries implanted as xenografts into immunodeficient mice when exposed to PRA in vivo. Furthermore, human artery graft ECs activated by binding of PRA and deposition of nonlytic mouse MAC in vivo show augmented T cell-mediated CAVlike lesions when retransplanted into recipient mice previously engrafted with T cells allogeneic to the artery segment.
Methods
Detailed experimental protocols are reported in the expanded Materials and Methods section in the online-only Data Supplement. All experiments using human materials were approved by the relevant Institutional Review boards and those involving animals by the Yale Institutional Animal Care and Use Committee. In vitro studies of human EC responses were conducted using multiple different isolates of serially passaged human umbilical vein ECs (HUVECs) pretreated with IFN-γ to restore in situ levels of class I and II HLA molecule expression. Deidentified high-titer PRA sera were obtained from the Yale-New Haven Hospital HLA typing laboratory. HUVEC responses to PRA sera, control sera, components of these sera, isolated complement components, or other agents were assessed by flow cytometry, immunofluorescence microscopy, Western blotting, reporter genes, expression microarrays, or real-time quantitative reverse transcription--polymerase chain reaction. CD4 + memory T cells were isolated from peripheral blood mononuclear cells collected by leukapheresis, and interactions with ECs were analyzed for adhesion under flow or for activation in response to direct recognition of nonself HLA molecules by flow cytometry or ELISA. Deidentified human renal allograft biopsies were analyzed by immunofluorescence microscopy. Responses of human artery xenografts in immunodeficient mice were analyzed by histology, morphometric analyses, immunofluorescence microscopy, and quantitative reverse transcription polymerase chain reaction. Student's t test, ANOVA, and Mann-Whitney analyses were performed with Origin computer software (Northampton, MA). Two-sided P values are presented in the text; values of P<0.05 were considered significant.
Results

High-Titer PRA Deposits Alloantibody and Sublytic Complement on ECs, Potentiating EC-Mediated Recruitment and Activation of Alloimmune CD4 + T Cells
High-titer PRA sera from transplantation candidates with >80% class I or II HLA reactivity have an IgG subtype distribution similar to that of control non-PRA sera (NPRA; n=4; Figure 1A , top). All 4 human IgG subtypes, including both IgG 1 and IgG 3 , subtypes that efficiently fix complement, bind to allogeneic HUVECs, indicative of the polyclonal nature of PRA (n=4; Figure 1A , bottom). IFN-γ pretreatment, which increases the expression of class I and induces class II HLA antigens on cultured ECs to in situ levels of expression, increased IgG binding and permitted efficient early and terminal complement binding to HUVECs as assessed by C4d and polyC9 staining, respectively ( Figure 1B) . ECs express several different complement regulatory proteins that contribute to resistance to lysis. We observed no significant change in surface expression of any of these complement regulatory molecules as a consequence of PRA treatment ( Figure 1C , top), but EC viability was similar after treatment with PRA sera for 4 hours compared with control sera lacking anti-HLA antibodies ( Figure 1D ). Viability remained comparable to that of ECs exposed to NPRA or to ECs treated with complementinactivated PRA (CIPRA) sera for at least 72 hours after treatment ( Figure 1E , left), consistent with prior reports demonstrating EC survival after in vitro assembly of MAC. [21] [22] [23] [24] [25] EC viability is reduced during incubation with allogeneic CD4 + T cells. To assess whether treatment with PRA sera affected EC viability in this setting, HUVECs were pretreated with vehicle, CIPRA, or PRA for 6 hours and then cocultured with allogeneic memory CD4 + T cells for up to 7 days. PRA-treated ECs showed slightly increased viability compared with controls ( Figure 1E , right).
We next assessed the effect of PRA and MAC deposition on the ability of ECs to recruit and activate CD4 + T cells. For T cell recruitment, IFN-γ-pretreated ECs were incubated with PRA, CIPRA, or vehicle, and human memory CD4 + T cells were flowed over the monolayer. PRA-treated ECs captured significantly more CD4 + T cells than CIPRA-or vehicle-treated ECs ( Figure 1F ). To examine whether PRA treatment altered the immunogenicity of ECs, IFN-γ-pretreated ECs were incubated with PRA, CIPRA, or vehicle and then cocultured with human allogeneic memory CD4 + T cells for 7 days. Incubation with PRA significantly increased the proliferative responses of CD4 + T cells, assessed by carboxyfluorescein succinimidyl ester (CSFE) dilution ( Figure 1G , top), and IFN-γ synthesis, assessed by intracellular cytokine staining ( Figure 1G , middle). Increased Th1-like cytokine elaboration was confirmed by ELISA of culture supernatants ( Figure 1G , bottom). We concurrently observed increased production of interleukin-4 and interleukin-17 by CD4 + T cells (data not shown), indicating activation of multiple memory T-helper subpopulations. Complement inactivation significantly reduced but did not completely abolish the ability of PRA to potentiate the immunogenicity of ECs, suggesting some effect of alloantibody binding that may be independent of complement ( Figure 1F and 1G).
Alloantibody Plus Complement Initiates a Proinflammatory Gene Program in PRA-Treated ECs
To further characterize PRA-induced EC changes, we performed microarray analyses of HUVECs treated with PRA sera (alloantibody plus complement activation), CIPRA sera (alloantibody but no complement activation), NPRA (serum were detected by flow cytometry in HUVECs pretreated with or without interferon-γ (IFN-γ; 50 ng/mL) for 48 to 72 hours and treated with PRA sera in gelatin veronal buffer for 2 hours (B). Error bars indicate standard deviations. CD46, CD55, and CD59 expression was assessed by flow cytometry at the indicated times (C). Annexin V and propidium iodide staining in CD31 + gated cells was assessed by flow cytometry (D, left and right). Viability was measured by Trypan blue exclusion at various times in HUVECs pretreated with IFN-γ for 48 to 72 hours before the addition of PRA (E, left). HUVECs were pretreated with vehicle, complement-inactivated PRA (CIPRA), or PRA for 6 hours and cocultured with allogeneic CD4 + CD45RA − HLA-DR − T cells. Annexin V staining in CD31 + gated cells was assessed by flow cytometry at the indicated times (E, right). *P<0.05 in pairwise comparisons with vehicle-treated ECs. CD4 + CD45RA − HLA-DR − T cells were flowed over confluent HUVEC monolayers pretreated with vehicle, CIPRA, or PRA for 24 hours. Captured T cells were quantified by immunostaining (F). CD4 + CD45RA − HLA-DR − T cell proliferative responses (G, top) and intracellular cytokine production (G, middle) were measured 7 days after coculture with HUVECs given the indicated pretreatments for 4 hours. Elaborated Th1-like cytokine in culture supernatants was measured by ELISA 24 hours after the addition of T cells (G, bottom). All assays were conducted at least 3 times with similar results; representative data are shown. CFSE indicates carboxyfluorescein succinimidyl ester. factors only), or vehicle. Principal component analysis showed that PRA sera initiated a gene expression program in ECs that was globally distinct from other treatment groups (Figure 2A , left, and Figure Ia-Ic in the online-only Data Supplement). CIPRA also had some effect on gene expression relative to NPRA ( Table I in the online-only Data Supplement), confirming that alloantibody can alter gene expression in ECs. 26 By unsupervised hierarchical clustering, we observed that, compared with CIPRA, PRA reproducibly induced multiple inflammatory genes, including chemokines, cytokines, cytokine receptors, and adhesion molecules (Figure 2A , right, and Tables II and III in the online-only Data Supplement. We selected CCL5, CCL20, interleukin-6, SELE (E-selectin), and vascular cell adhesion molecule-1 (VCAM-1) for validation on the basis of their reproducible and significant upregulation in microarray analyses and their previously characterized roles in inflammation. We confirmed that PRA sera increased mRNA expression of this subset of inflammatory genes assessed by real-time quantitative reverse transcription-polymerase chain reaction ( Figure 2B , left) and increased protein expression for the last 2 molecules assessed by flow cytometry ( Figure 2B , right).
MAC Formation Is Necessary for Proinflammatory Gene Expression in PRA-Treated ECs
To analyze the contributions of alloantibody and complement to EC activation, PRA sera were separated into IgG + fractions containing alloantibody and IgG − fractions containing complement. Neither fraction alone could deposit C4d on ECs ( Figure 3A activation was required for full induction of this subset of proinflammatory genes in PRA sera-treated HUVECs. Neutralizing antibodies to C3a and C5a did not inhibit the response to PRA when added before or after the addition of PRA ( Figure 3D , left and right). However, compared with the PRA IgG + fraction combined with NPRA serum, the response was markedly diminished when combined with C6-or C9-deficient sera ( Figure 3E , left), suggesting that MAC formation is necessary for full induction of inflammatory gene expression. To determine whether alloantibody is necessary for the alterations induced in HUVECs by PRA, we assembled MAC on the surface of ECs using isolated terminal complement components. In vitro formation of MAC elicited some inflammatory gene expression compared with untreated controls, but at significantly lower levels than intact PRA ( Figure 3E , right), likely because MAC assembled from purified components was expressed at lower levels than MAC assembled from PRA sera on EC ( Figure II in the online-only Data Supplement). Neither MAC formation nor inflammatory gene expression was increased by adding PRA IgG + fractions after assembly of MAC with late complement components ( Figure II in the online-only Data Supplement and Figure 3E , right). Thus, alloantibody seems to function primarily to generate high levels of MAC, although a lesser direct effect of alloantibody was also observed.
MAC and Pore-Forming Compounds Selectively Activate Noncanonical NF-κB Signaling in ECs
Pathway analysis and cross-referencing of public gene databases indicated that a significant subset of genes upregulated by PRA in ECs are regulated by NF-κB (Table  IV in the online-only Data Supplement). We therefore analyzed NF-κB activation using HUVECs transfected with an NF-κB luciferase reporter that responds to both tumor necrosis factor-α (TNF-α) or LIGHT, cytokine activators of canonical and noncanonical NF-κB signaling, respectively ( Figure 4A , bottom). ECs treated with PRA showed increased luciferase activity compared with vehicle-, CIPRA-, and complement-deficient sera-treated controls ( Figure 4A, top) , suggesting complement-induced NF-κB activation. To test which pathway was activated by PRA, we compared ECs treated with PRA and ECs treated with TNF-α. TNF-α, but not PRA, induced IκBα degradation ( Figure 4B , top, and Figure III in the online-only Data Supplement). PRA, but not TNF-α, induced partial processing of p100 to p52 (Figure 4B , middle) and increased levels of NF-κB-inducing kinase (NIK; Figure 4B , bottom). No changes in IκBα, p52, or NIK levels in vehicle-treated controls were observed (data not shown). Immunofluorescence microscopy further revealed that PRA induced nuclear translocation of p52 and relB but not of p65 subunits of NF-κB ( Figure 4C and Figure IV in the online-only Data Supplement) and confirmed that PRA increased NIK expression ( Figure 4D ). These responses indicate that PRA selectively activates the noncanonical NF-κB pathway.
To investigate whether MAC activated noncanonical NF-κB signaling through pore formation, sublytic concentrations of melittin and ionomycin, alternative pore-forming compounds, were added to HUVEC cultures. Both melittin and ionomycin induced p52 processing and increased NIK expression ( Figure 4E ), suggesting that noncanonical NF-κB activation may indeed occur in response to sublytic surface pore formation on ECs.
Noncanonical NF-κB Signaling in ECs Is Required for PRA-Mediated Activation of Allogeneic T Cells
To explore the relationship of noncanonical NF-κB signaling and EC activation in response to PRA, we performed siRNA-mediated knockdown of NIK or p100, essential components of noncanonical NF-κB signaling, and observed inhibition of the increase in mRNA expression of 5 proinflammatory genes (CCL5, CCL20, interleukin-6, E-selectin, and VCAM-1) induced by PRA ( Figure 5A ). NIK or p100 knockdown also decreased the number of CD4 + T cells captured by PRA-treated HUVECs under flow conditions ( Figure 5B ). To investigate the significance of PRA-induced VCAM-1 expression, we confirmed that PRA treatment induced VCAM-1 protein and demonstrated that NIK knockdown reduced VCAM-1 protein expression induced by PRA treatment (Figure 5C , left). Treatment of PRA-activated HUVECs with blocking antibody against VCAM-1 significantly abrogated T-cell adhesion to the EC monolayer compared with treatment with isotype antibody control under flow conditions ( Figure 5C, right) , identifying VCAM-1 as a PRA-induced molecule that can functionally alter EC interactions with T cells. Additionally, knockdown of NIK or p100 significantly abrogated the enhanced proliferation of ( Figure 5D , left) and cytokine secretion by ( Figure 5D , right) allogeneic memory CD4 + T cells cocultured with PRA-treated ECs. Thus, the enhanced immunological functions of EC after PRA treatment and MAC formation are significantly dependent on noncanonical NF-κB signaling.
Noncanonical NF-κB Activation in Peritubular Capillaries in CAMR Patients and in Human Arterial Intima In Vivo
To test whether noncanonical NF-κB activation occurs in human graft ECs, we used immunofluorescence to compare renal allograft biopsies from 3 patients who had developed graft dysfunction in the setting of a DSA and who showed C4d deposition on peritubular capillary ECs, indicative of CAMR with biopsies from 3 transplantation patients with preserved renal function lacking DSA and C4d positivity. We found both significantly increased p52 nuclear staining ( Figure 6A ) and NIK expression ( Figure 6B ) in ECs in all 3 CAMR + patients compared with CAMR − patients ( Figure 6C ).
Because CAV is most evident in epicardial and intramyocardial arteries, vessels not typically sampled in endomyocardial biopsies of cardiac allografts, we used a humanized mouse model of CAV to determine whether antibody-and complement-induced noncanonical NF-κB activation can occur in human arterial ECs in vivo. 10 Adjacent segments of human artery branches were interposed into the infrarenal aortas of pairs of immunodeficient mice and allowed to quiesce for 30 days. Hosts were then injected with PRA sera or PRA sera depleted of IgG, and the grafts were harvested 24 hours later and examined by immunofluorescence. Grafts exposed to intact PRA sera, but not IgG-depleted PRA sera, showed binding of human IgG and mouse C4d and poly C9 on human ECs, the latter identified by Ulex europeous agglutinin I ( Figure 6D and Figure . Arterial grafts were harvested 18 to 24 hours after injection with intact PRA sera or IgG-depleted PRA sera and immunostained (F, top); intragraft gene transcripts were quantified by reverse transcription-polymerase chain reaction normalized to CD31 (F, bottom); and p52 nuclear staining and NIK cell staining were assessed (G; n=5 pairs). After treatment with PRA sera or IgG-depleted PRA sera for 18 to 24 hours, human arterial segments were retransplanted into naive SCID/beige recipients. Grafts were harvested at 3 weeks, stained, and quantified for IgG, polyC9, and NIK (H; scale bars, 200 µm). *P<0.05 comparing CAMR patients and healthy patient controls or PRA sera-treated samples and IgG − PRA sera-treated controls. IL6 indicates interleukin-6; and VCAM1, vascular cell adhesion molecule-1.
of MAC, PRA treatment did not cause intimal denudation (Figure 6E, left) , and the number of DAPI-stained nuclei within cells costained with Ulex europeous agglutinin I did not differ significantly between these treatment groups (Figure 6E, right) . PRA activated the ECs as assessed by induction of E-selectin and VCAM-1 in the PRA-treated, but not the control-treated, vessels (Figure 6F , top, and Figure Vb) . Quantitative reverse transcription-polymerase chain reaction analysis further revealed significant increases in inflammatory gene expression in grafts treated with intact PRA compared with controls ( Figure 6F , bottom). Graft ECs with bound IgG and C4d also showed significantly elevated expression of p52 + nuclei (P=0.004) and NIK (P=0.000002) compared with the controls (Figure 6G) , consistent with noncanonical NF-κB activation. To assess durability of noncanonical activation, hosts bearing arterial grafts were injected with PRA or IgG-depleted PRA sera. Twenty-four hours later, grafts were retransplanted into naive immunodeficient hosts and harvested 1, 2, or 3 weeks later. Grafts treated with IgG-depleted PRA sera showed no detectable IgG, C4d, polyC9, or NIK staining at any time point. PRA-treated grafts showed C4d staining that was retained for 3 weeks, whereas IgG and polyC9 expression was significantly diminished at 1 week after retransplantation (data not shown) and was gone by 2 weeks after retransplantation. Like C4d staining, increased NIK expression persisted in PRA sera-treated grafts for the full 3 weeks ( Figure 6H ).
PRA Elicits CAV-Like Lesions in a T Cell-Dependent Manner
To examine the effect of PRA serum-treated ECs on intimal T-cell responses, we injected PRA sera or IgG-depleted PRA sera into immunodeficient paired hosts bearing quiesced human arterial segments. Each graft was harvested and retransplanted 24 hours later into a second immunodeficient host that, in some cases, had previously been engrafted with human T cells allogeneic to the artery donor. In this experimental design, circulating leukocytes in the second mouse host are not directly exposed to the PRA sera, circumventing potential confounding effects of PRA on F c R-bearing mouse leukocytes and on adoptively transferred human T cells expressing HLA molecules. Grafts exposed to PRA sera and implanted into mice lacking human T cells showed Figure 7 . Panel-reactive antibody (PRA) elicits cardiac allograft vasculopathy-like lesions in a T cell-dependent manner. Grafts treated with PRA sera or IgG-depleted PRA sera for 18 to 24 hours were retransplanted into naive severe combined immunodeficiency disease (SCID)/beige hosts. Hosts with PRA-treated xenografts and without circulating human CD3 + T cells at 1 week showed significantly increased intimal infiltration of Gr-1 + and CD45 + myeloid cells compared with hosts treated with IgG-depleted PRA sera (A; scale bars, 400 µm). However, 3 weeks after retransplantation, xenografts treated with PRA sera showed no morphological differences compared with hosts receiving xenografts treated with IgG-depleted PRA sera (B; scale bars, 400 µm). Arterial xenografts treated with PRA or IgGdepleted PRA sera (scale bars, 400 µm) and reimplanted into naive SCID/beige hosts engrafted with human CD3 + T cells were harvested 3 weeks later and assessed for intimal infiltrating CD45RO + T cells (C, left) and intimal areas (C, right) . At 2 weeks after retransplantation, intimal CD3 + and CD3 + IFN-γ + T cells were quantified by immunofluorescence (D; scale bars, 400 µm), intragraft proinflammatory gene transcripts were normalized to CD31 (E, left), and T cell-associated transcripts, CD4, and interferon-γ (IFN-γ; IFNG in E) were normalized to GAPDH and CD4 (right graph). *P<0.05 comparing PRA sera-treated samples with IgG − PRA sera-treated controls. IL6 indicates interleukin-6; and VCAM1, vascular cell adhesion molecule-1. December 3/10, 2013 significantly enhanced recruitment of murine Gr-1 + myeloid cells (P=0.02) or CD45 + leukocytes (P=0.04) 1 week after transplantation compared with controls treated with IgGdepleted PRA sera ( Figure 7A ; n=6 pairs). However, by 3 weeks after retransplantation, no morphological differences could be discerned between arteries that had been exposed to intact PRA sera compared with those exposed to IgGdepleted PRA sera ( Figure 7B; n=3 pairs) . In contrast, arterial segments reimplanted into hosts previously engrafted with human T cells (n=7 pairs) showed greater numbers of intima-infiltrating T cells (Figure 7C, left) and increased intimal areas (Figure 7C , right) at 3 weeks after implantation compared with control treated grafts. PRA pretreatment also increased the numbers of intima-infiltrating human IFNγ-producing T cells ( Figure 7D ) with accordingly increased intragraft transcripts of proinflammatory genes (Figure 7E , left) and T cell-associated transcripts (Figure 7E, right) . These data indicate that PRA-treated human arterial xenografts develop enhanced CAV-like changes associated with increased infiltration of allogeneic T cells and intragraft IFN-γ expression.
Discussion
CAV is the major cause of late cardiac allograft loss and, unlike acute rejection, is pharmacologically untreatable. Development of new therapies has been hindered by a lack of relevant models to explore pathogenic mechanisms. 2, 3 We used PRA to model the complement-fixing effects of DSA and identified an alloantibody-and complementinduced signaling pathway involving noncanonical NF-κB signaling components in graft ECs that results in enhanced EC-mediated recruitment and activation of host alloreactive T cells. Noncanonical NF-κB signaling thus represents a novel and attractive target for the development of pharmacotherapeutics.
Distinct lines of evidence have favored pathogenic roles for either T-cell infiltration and IFN-γ secretion [4] [5] [6] [7] [8] [9] [10] 12 or development of a DSA and activation of complement [13] [14] [15] in CAV. Specifically, the pathogenic role of T cells has been investigated using analysis of human tissues and by experiments with various murine knockout models or humanized mice. 12 The pathogenic effects of alloantibodies on ECs have been studied using in vitro incubation [27] [28] [29] [30] or in vivo injection of monoclonal murine anti-HLA antibody. 31, 32 The proinflammatory effects of MAC have been modeled using in vitro assembly of MAC. [21] [22] [23] [24] [25] Our results support the conclusion that these elements can act in concert. Alloantibody is required for high-level deposition of terminal complement on ECs ( Figure 3E and Figure II in the online-only Data Supplement). Terminal complement, in turn, initiates a durable activation signal to affected ECs that can last for weeks in vivo ( Figure 6H ), driving proinflammatory genes that enable the ECs to exacerbate T cell-mediated changes in the artery wall characteristic of CAV ( Figure 7C and 7D) . Our findings do not rule out a role for T cells, antibody, or complement acting independently; instead, they suggest that graft ECs, the major cell population expressing graft HLA antigens in the vessel wall, may serve to integrate these signals.
PRA upregulated proinflammatory genes without a significant increase in cell death in human ECs in vitro ( Figure 1E ) and in vivo. Indeed, PRA-treated ECs may actually resist cell death better when cocultured with T cells. Resistance to death by PRA may depend in part on the expression of complement regulatory proteins by ECs ( Figure 1C ). The survival of ECs under these circumstances may also depend on the induction of the many prosurvival genes known to be regulated by NF-κB. 22 If prosurvival genes are induced in vivo, rather than reduce vasculopathy, they may contribute to persistent stimulation of host alloimmunity by graft ECs in patients with CAMR. 16, 17 Alloantibody and complement have previously been shown to modulate function of leukocytes. F c receptor-bearing macrophages 31 and natural killer cells 32 can respond to IgG bound to EC surfaces. Moreover, anaphylatoxins locally synthesized by ECs can enhance alloimmune T-cell responses. [33] [34] [35] By using a retransplantation strategy whereby host immune cells were not directly exposed to PRA, we avoided potentially confounding effects of direct alloantibody or complement binding to leukocytes. These results therefore do not contradict prior reports showing enhanced immune function resulting from locally synthesized anaphylatoxins 34, 35 but rather support an additional mechanism of pathology whereby EC-bound alloantibody and complement potentiate the capacity of ECs to promote alloreactive T-cell recruitment and activation.
Noncanonical NF-κB signaling has been associated with signaling through TNF receptor superfamily members such as LIGHT or Toll-like receptors using TRIF. 36 As in our study, other pathways of noncanonical signaling are driven by increased protein levels of NIK, leading to partial processing of p100 to p52. The increase in NIK results from protein stabilization rather than increased transcription and depends on recruitment of cIAP1 (Cellular Inhibitor of Apoptosis Protein), cIAP-2, and TRAF3 (Tumor Necrosis Factor Receptor Associated Factor) to the activated receptor signaling complex. In this setting, TRAF3 is ubiquitinylated by cIAPs and degraded, whereas basal ubiquitinylation and proteolytic degradation of NIK, normally mediated by the same cIAPs, decline, leading to a rise in NIK expression levels. The rise in NIK levels is generally slow, requiring several hours, and contributes mostly to lymphoid organogenesis or the late augmentation of inflammation mediated at earlier times by canonical signaling. NIK levels induced by MAC also correlate with protein stabilization rather than new transcription but are rapid, do not correlate with TRAF3 degradation, and remain durably elevated up to 3 weeks after a single PRA injection ( Figure 6E and unpublished observations, D.J.). The rapidly inducible and durable qualities of noncanonical NF-κB signaling caused by MAC may underlie its role in the slow and chronic progression of CAV.
Although the present study was undertaken to better understand how DSA and complement could increase the incidence of CAV, our findings may be of much more generalized import. Similar changes induced by alloantibody and complement in microvessels of other solid-organ transplants may lead to delayed organ-specific complications analogous to CAV, for example, CAMR and bronchiolitis obliterans in renal and pulmonary allografts, respectively. Furthermore, it is possible that autoantibodies reactive with other EC antigens or immune complexes that form or deposit in a subendothelial location may also lead to MAC formation on the EC surface and may exert similar effects, contributing to vascular complications associated with connective tissue disorders such as systemic lupus erythematosus or rheumatoid arthritis. If such an association exists, there may be much more general applicability in pharmacotherapeutics that target MAC-activated noncanonical NF-κB signaling. Patient-derived biopsies and sera from such populations, modeled on our experiments, could be used to investigate these possibilities.
